Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1

Status

Terminated 2Recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1Breast 1

Conditions

Triple Negative Breast Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Myelodysplastic Syndromes 1Leukemia, Myeloid, Acute 1Iron Overload 1

Interventions

Cyclophosphamide 241Radiotherapy 217Gemcitabine 187Cisplatin 185Carboplatin 182Docetaxel 166Bevacizumab 166Paclitaxel 144Capecitabine 142Rituximab 141pembrolizumab 140Nivolumab 126Oxaliplatin 124Dexamethasone 122Fluorouracil 113fludarabine 104Radiosurgery 101Doxorubicin 99fludarabine phosphate 97Irinotecan 96Etoposide 95Lenalidomide 93Cytarabine 92Magnetic Resonance Spectroscopy 90Radiation 89Filgrastim 89Leucovorin 88Bortezomib 86Cetuximab 80Pemetrexed 79

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × OTHER × Deferoxamine × Clear all
NCT05300958 2025-07-22

Deferoxamine Plus Chemotherapy for Metastatic Triple Negative Breast Cancer

Sun Yat-sen University

Phase 2 Terminated
25 enrolled
Breast

Triple Negative Breast Neoplasms

NCT00658411 2013-04-09

Deferoxamine for Iron Overload Before Allogeneic Stem Cell Transplantation

Dana-Farber Cancer Institute

Phase NA Terminated
5 enrolled 8 charts
LymphoidMyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Iron Overload, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡